Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1084240 | PMC |
| http://dx.doi.org/10.1093/embo-reports/kvf187 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Causes and Consequences of Delayed Presentation of Muscle Invasive Urinary Bladder Carcinoma.
Mymensingh Med J
January 2025
Dr Md Fazlul Haq Siddique, Associate Professor, Department of Urology, Mymensingh Medical College (MMC), Mymensingh, Bangladesh; E-mail:
Lag times for the diagnosis and treatment of urinary bladder cancer are generally longer which reduces the chances of achieving cures. This study was carried out at the Urology Department of Bangabandhu Sheikh Mujib Medical University, Dhaka and a Urology Center in a private hospital in Dhaka, Bangladesh from July 2007 to June 2008 on patients of newly diagnosed muscle invasive bladder carcinoma. This study was intended to assess the delay encountered by the patients and its consequences in the process of diagnosis and treatment of bladder cancer.
View Article and Find Full Text PDFRisk of bleeding in pulmonary embolism patients concomitant with COVID-19 undergoing extended anticoagulation: A multicenter cohort study.
Thromb Res
December 2024
The First Clinical Medical College, Shanxi Medical University, Taiyuan, China; National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China; Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. Electronic address:
Introduction: The impact of Coronavirus disease 2019 (COVID-19) on clinical outcomes in pulmonary embolism (PE) patients receiving extended anticoagulation therapy is not fully understood. The study aimed to investigate the impact of the Omicron outbreak on patients with PE receiving extended anticoagulation therapy.
Materials And Methods: This prospective multicenter cohort study was conducted during the Omicron pandemic.
Medicare Local Coverage Determinations: Evidence Quality Is Stronger For Covered Indications.
Health Aff (Millwood)
December 2024
Sanket S. Dhruva University of California San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California.
Under the 21st Century Cures Act of 2016, a summary of the evidence used to support local coverage determinations, which represent the vast majority of Medicare's coverage decisions for new technologies, must be made publicly accessible. Using reports from the Medicare Coverage Database on local coverage determinations and the medical literature, we examined the availability of these decisions and the quality of evidence cited for therapeutic drugs, biologics, and moderate- or high-risk devices during the period 2015-22 to understand whether evidence strength and generalizability differed for indications with favorable versus unfavorable coverage decisions. Evidence summaries were publicly available for 26 percent of coverage decisions originally effected during 2015-18 and 100 percent during 2019-22.
View Article and Find Full Text PDFDelphi-driven consensus definition for mesenchymal stromal cells and clinical reporting guidelines for mesenchymal stromal cell-based therapeutics.
Cytotherapy
February 2025
Sinclair Center for Regenerative Medicine, Ottawa Hospital Research Institute, Ottawa, Canada; Neonatology, Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada; Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada. Electronic address:
Background Aims: Despite promising results in pre-clinical studies, mesenchymal stromal cells (MSCs) face significant challenges in clinical translation. A scoping review by our group highlighted two key issues contributing to this gap: (i) lack of a clear and consensus definition for MSCs and (ii) under-reporting of critical parameters in MSC clinical studies. To address these issues, we conducted a modified Delphi study to establish and implement a consensus definition for MSCs and develop reporting guidelines for MSC clinical studies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!